Abstract
Ethical aspects on human gene therapy are briefly discussed, in relation to the protocol developed in Duchenne/Becker muscular dystrophy with a full-length dystrophin plasmid. Differences between somatic therapies--as considered in this study--and germline gene interventions are underlined. Regulatory aspects for France are summarized. Special emphasis is put on the necessary control of publicity in the lay media in such a clinical study.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
MeSH terms
-
Animals
-
Clinical Protocols
-
DNA / therapeutic use
-
Dystrophin / deficiency
-
Dystrophin / genetics*
-
Dystrophin / therapeutic use
-
Ethics, Medical*
-
France
-
Genetic Therapy / ethics*
-
Genetic Therapy / legislation & jurisprudence*
-
Genetic Therapy / methods
-
Humans
-
Mass Media / standards
-
Muscular Dystrophy, Duchenne / genetics
-
Muscular Dystrophy, Duchenne / therapy*
-
Plasmids / genetics*